Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genentech, Inc. v. Eli Lilly and Company
Case Number:
3:18-cv-01518
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 23, 2021
Eli Lilly Loses $10M Fee Bid Over Genentech's Dropped IP Suit
A California federal judge on Tuesday rejected Eli Lilly & Co.'s bid for $10 million in attorney fees alleging Genentech Inc. dragged out litigation before dropping its patent suit over a psoriasis drug while noting Genentech unreasonably failed to tell the USPTO about a Federal Circuit decision weakening its claim to patent protection.
-
May 01, 2020
Genentech Blasts Eli Lilly's $10M Fee Bid For Dropped IP Suit
Genentech has told a California federal court that it acted in good faith when it accused Eli Lilly of infringing its patent through the sale of a psoriasis drug and therefore should not have to cover the $10 million Eli Lilly says it spent fending off the suit.
-
April 02, 2020
Eli Lilly Says Genentech Owes $10M In 'Unwinnable' Suit Fees
Genentech knew it had no case when it accused Eli Lilly in California federal court of infringing its patent through the sale of a psoriasis drug, the latter said Wednesday in a bid to get Genentech to cover the $10 million it spent on attorney fees while fending off the suit.
-
July 05, 2018
Genentech Sues Eli Lilly For Violating Just-Issued Drug Patent
Genentech has sued Eli Lilly for infringing the asserted claims of a just-issued patent through sales of Taltz, a psoriasis drug that has been on the market since 2016, according to a complaint filed in the Southern District of California.